Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2019: Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type – ResearchAndMarkets.com
April 16, 2019DUBLIN–(BUSINESS WIRE)–The “Post-Traumatic
Stress Disorder (PTSD) – Pipeline Review, H1 2019” drug
pipelines has been added to ResearchAndMarkets.com’s
offering.
Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete
with analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)
pipeline guide also reviews of key players involved in therapeutic
development for Post-Traumatic Stress Disorder (PTSD) and features
dormant and discontinued projects. The guide covers therapeutics under
Development by Companies/Universities/Institutes, the molecules
developed by Companies in Phase III, Phase II, Phase I, Preclinical,
Discovery and Unknown stages are 1, 2, 4, 19, 6 and 2 respectively.
Similarly, the Universities portfolio in Phase III, Preclinical and
Discovery stages comprises 1, 3 and 1 molecules, respectively.
Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline
guide helps in identifying and tracking emerging players in the market
and their portfolios, enhances decision making capabilities and helps to
create effective counter strategies to gain competitive advantage.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous
System). -
The pipeline guide reviews pipeline therapeutics for Post-Traumatic
Stress Disorder (PTSD) (Central Nervous System) by companies and
universities/research institutes based on information derived from
company and industry-specific sources. -
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
undisclosed stages. -
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
activities. -
The pipeline guide reviews key companies involved in Post-Traumatic
Stress Disorder (PTSD) (Central Nervous System) therapeutics and
enlists all their major and minor projects. -
The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD)
(Central Nervous System) therapeutics based on mechanism of action
(MoA), drug target, route of administration (RoA) and molecule type. -
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects. -
The pipeline guide reviews latest news related to pipeline
therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central
Nervous System)
Reasons to Buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies. -
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage. -
Find and recognize significant and varied types of therapeutics under
development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous
System). - Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies. -
Plan mergers and acquisitions meritoriously by identifying key players
and it’s most promising pipeline therapeutics. -
Formulate corrective measures for pipeline projects by understanding
Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)
pipeline depth and focus of Indication therapeutics. -
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope. -
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Key Topics Covered
1. Introduction
2. Post-Traumatic Stress Disorder (PTSD) – Overview
3. Post-Traumatic Stress Disorder (PTSD) – Therapeutics Development
4. Post-Traumatic Stress Disorder (PTSD) – Therapeutics Assessment
5. Post-Traumatic Stress Disorder (PTSD) – Companies Involved in
Therapeutics Development
6. Post-Traumatic Stress Disorder (PTSD) – Drug Profiles
7. Post-Traumatic Stress Disorder (PTSD) – Dormant Projects
8. Post-Traumatic Stress Disorder (PTSD) – Discontinued Products
9. Post-Traumatic Stress Disorder (PTSD) – Product Development Milestones
10. Appendix
Companies Mentioned
- Actinogen Medical Ltd.
- Addex Therapeutics Ltd.
- Amorsa Therapeutics Inc.
- Anagin Inc.
- Aptinyx Inc.
- Armgo Pharma Inc.
- Artelo Biosciences Inc.
- Azevan Pharmaceuticals Inc.
- Catalyst Pharmaceuticals Inc.
- Chronos Therapeutics Ltd.
- Corcept Therapeutics Inc.
- Eli Lilly and Co.
- Embera NeuroTherapeutics Inc.
- Immodulon Therapeutics Ltd.
- Johnson & Johnson
- Lixte Biotechnology Holdings Inc.
- NeuroNascent Inc.
- Omeros Corp.
- Otsuka Holdings Co. Ltd.
- Sanofi
- SpringWorks Therapeutics LLC
- Tonix Pharmaceuticals Holding Corp.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/xezxrm
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Mental
Disorders Drugs